SAN CARLOS, Calif., Nov. 5, 2018 /PRNewswire/ -- Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused
"Findings from these presentations add to the growing body of research supporting our hypothesis that factors in the plasma proteome can play an important modulatory role in neurodegenerative diseases, particularly cognitive dysfunction and neurodegeneration. This presents an entirely new opportunity for therapeutic interventions," said Steven Braithwaite, Ph.D., chief scientific officer of Alkahest.
Poster Presentation Title: Synergistic effects of a plasma fraction and exercise on neurogenesis Presenter: I. GALLAGERDate: Monday, November 5, 2018Session Time: 8:00 a.m. – 12:00 p.m. PTSession: Neurogenesis and Gliogenesis: Neuronal Development I
Poster Presentation Title: Longitudinal characterization of plasma fraction efficacy on neurogenesis in aging mice Presenter: R. A. ESTRADADate: Monday, November 5, 2018 Session Time: 8:00 a.m. – 12:00 p.m. PTSession: Neurogenesis and Gliogenesis: Neuronal Development I
Poster Presentation Title: Human plasma fraction prevents age-dependent decline in neuronal activity, neurogenesis, and neuroinflammation in C57BL6 micePresenter: M. K. CAMPBELLDate: Monday, November 5, 2018Session Time: 8:00 a.m. – 12:00 p.m. PTSession: Brain Wellness and Aging: Pharmacological and Non-Pharmacological Interventions
Presentation Title: Multi-modal impact of treatment with a human plasma protein fraction to enhance CNS functionPresenter: E. CZIRRDate: Monday, November 5, 2018Session Time: 1:00 p.m. – 2:45 p.m. PTSession: Brain Wellness and Aging: Systemic Factors and Brain Function
Presentation Title: Identification and characterization of a beneficial plasma fraction with long term efficacy in the CNS Presenter: V. KHEIFETSDate: Monday, November 5, 2018Session Time: 1:00 p.m. – 2:45 p.m. PTSession: Brain Wellness and Aging: Systemic Factors and Brain Function
Poster Presentation Title: Treatment with a CCR3 antagonist rescues neuroinflammation and cognitive dysfunction in acute and chronic LPS models Presenter: S. REGEDate: Wednesday, November 7, 2018Session Time: 8:00 a.m. – 12:00 p.m. PT Session: Neurotoxicity, Inflammation, and Neuroprotection: Neuroinflammation: Animal Models
Poster Presentation Title: Human Plasma Fraction reduces the detrimental effects of alpha-synuclein overexpression in mice Presenter: C. TUNDate: Wednesday, November 7, 2018Session Time: 1:00 p.m. – 5:00 p.m. PT Session: Parkinson's Disease: Alpha-Synuclein: Models
About AlkahestAlkahest is a privately-held clinical-stage company based in the San Francisco Bay Area developing treatments for age-related diseases, with an emphasis on neurodegeneration — a key medical challenge for our generation. The company's breakthrough research has elucidated changes in the plasma proteome in healthy aging and age-related diseases, and demonstrated that factors in the blood plasma can be augmented or inhibited in order to reverse detrimental effects of aging in both normal aging and disease models in animals. Alkahest is developing novel plasma-based therapies in collaboration with Barcelona, Spain-based Grifols, a global healthcare company and leading producer of plasma therapies. For further information, see www.alkahest.com.
Contact Information:Joe McCrackenVice President Business DevelopmentAlkahest, Inc. email@example.com
Media Contact:Michael TattoryLifeSci Public Relations firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/alkahest-to-present-at-the-society-for-neuroscience-annual-meeting-300743366.html
SOURCE Alkahest Inc.
Subscribe to our Free Newsletters!